Business
Novo Nordisk Halts Two More Heart Trials of Its Anti-Inflammatory Drug
After the drug lowered inflammation but not heart attacks in a big Phase 3, a monitoring committee judged two follow-on trials unlikely to succeed — a setback for the “inflammation causes heart disease” strategy.